Holiday Notification: Cayman Chemical will be closed Monday, May 28, 2012, in observance of the Memorial Day holiday.
More…
Please feel free to continue placing orders via our website or via fax at 734-971-3640. You may send an email to customer service at custserv@caymanchem.com , or to technical support at techserv@caymanchem.com which we will respond to the next business day. Cayman will resume regular business hours and shipping schedules on Tuesday, May 29, 2012. Thank you for your patience and understanding.
Phosphodiesterases (PDE) enzymatically convert the cyclic nucleotide second messengers cAMP and cGMP to 5’-AMP and 5’-GMP, respectively, thus terminating signal transduction. The cAMP-specific PDE4 isoforms may be particularly important in certain respiratory and neurological diseases.1,2 CP 80633 is a selective inhibitor of PDE4 (IC50 = 1.27 μM for PDE4 versus. >100 μM for PDE1, PDE2, PDE3, and PDE5).3 It potentiates PGE1-dependent increases in cAMP levels in eosinophils, monocytes, and T-cells, inhibits eosinophil superoxide production (IC50 < 0.6 μM), and blocks LPS-induced TNF-α release from monocytes (IC50 = 0.22 μM).3 CP 80633 (1 mg/kg) significantly reduces antigen-induced airway inflammation in atopic guinea pigs, monkeys, and mice.4,5
1
Spina, D. PDE4 inhibitors: Current status. Br J Pharmacol155308-315(2008).
2
O'Donnell, J.M., and Zhang, H. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci25(3)158-163(2004).
3
Cohan, V.L., Showell, H.J., Fisher, D.A., et al. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633. J Pharmacol Exp Ther278(3)1356-1361(1996).
4
Turner, C.R., Cohan, V.L., Cheng, J.B., et al. The in vivo pharmacology of CP-80, 633, a selective inhibitor of phosphodiesterase 4. J Pharmacol Exp Ther278(3)1349-1355(1996).
5
Cheng, J.B., Watson, J.W., Pazoles, C.J., et al. The phosphodiesterase type 4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor-α (TNFα) production in mice: Effect of adrenalectomy. J Pharmacol Exp Ther280621-626(1997).
Cohan, V.L., Showell, H.J., Fisher, D.A., et al. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633. J Pharmacol Exp Ther278(3)1356-1361(1996).
Spina, D. PDE4 inhibitors: Current status. Br J Pharmacol155308-315(2008).
O'Donnell, J.M., and Zhang, H. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci25(3)158-163(2004).
Cheng, J.B., Watson, J.W., Pazoles, C.J., et al. The phosphodiesterase type 4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor-α (TNFα) production in mice: Effect of adrenalectomy. J Pharmacol Exp Ther280621-626(1997).
Turner, C.R., Cohan, V.L., Cheng, J.B., et al. The in vivo pharmacology of CP-80, 633, a selective inhibitor of phosphodiesterase 4. J Pharmacol Exp Ther278(3)1349-1355(1996).